A behavioural comparison of acute and chronic Delta(9)-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice
Cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing schizophrenia. The behavioural profiles of the psychotropic cannabis constituent Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and the non-psychotomimetic constituent cannabidiol (CBD) were investigated with a battery of behavioural tests relevant to anxiety and positive, negative and cognitive symptoms of schizophrenia. Male adult C57BL/6JArc mice were given 21 daily intraperitoneal injections of vehicle, Delta(9)-THC (0.3, 1, 3 or 10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg). Delta(9)-THC produced the classic cannabinoid CB1 receptor-mediated tetrad of hypolocomotion, analgesia, catalepsy and hypothermia while CBD had modest hyperthennic effects. While sedative at this dose, Delta(9)-THC (10 mg/kg) produced locomotor-independent anxiogenic effects in the open-field and light dark tests. Chronic CBD produced moderate anxiolytic-like effects in the open-field test at 50 mg/kg and in the light-dark test at a low dose (1 mg/kg). Acute and chronic Delta(9)-THC (10 mg/kg) decreased the startle response while CBD had no effect. Prepulse inhibition was increased by acute treatment with Delta(9)-THC (0.3, 3 and 10 mg/kg) or CBD (1, 5 and 50 mg/kg) and by chronic CBD (1 mg/kg). Chronic CBD (50 mg/kg) attenuated dexamphetamine (5 mg/kg)-induced hyperlocomotion, suggesting an antipsychotic-like action for this cannabinoid. Chronic Delta(9)-THC decreased locomotor activity before and after dexamphetamine administration suggesting functional antagonism of the locomotor stimulant effect. These data provide the first evidence of anxiolytic- and antipsychotic-like effects of chronic but not acute CBD in C57BL/6JArc mice, extending findings from acute studies in other inbred mouse strains and rats.
|Authors||Long, L. E.; Chesworth, R.; Huang, X. F.; McGregor, I. S.; Arnold, J. C.; Karl, T.;|
|Publisher Name||INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY|
|URL link to publisher's version||<Go to ISI>://CCC:000280934600003|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/10825|